Loading clinical trials...

RECRUITING

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

NCT06243588•Istituto Ortopedico Rizzoli

Summary

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

Eligibility

Age

2 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021
•Age ≥ 2 years
•Diagnosis of Ewing Sarcoma
•Patients with available clinical and imaging data

Exclusion Criteria

•At least one inclusion criterion not met

Locations (1)

IRCCS Itituto Ortopedico Rizzoli

Bologna, BO, Italy

Key Dates

Start Date

January 25, 2024

Primary Completion Date

December 31, 2025

Completion Date

December 31, 2025

Last Updated

March 5, 2025

Enrollment

400

ESTIMATED participants

Conditions

Ewing Sarcoma

Interventions

clinical records review

OTHER

Contacts

Costantino Errani

CONTACT

0516366 costantino.errani@ior.it

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

NCT03715933

Ewing Sarcoma

View study

RECRUITINGPHASE1/PHASE2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

NCT06541262

NeuroblastomaEwing Sarcoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 5, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Inclusion Criteria

Exclusion Criteria

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Lurbinectedin in FET-Fused Tumors

Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas

Observational Study on Skeletal Ewing's Sarcoma